Inventor · disambiguated record
Bryan D. Smith
Also filed as: SMITH BRYAN · SMITH BRYAN D · SMITH BRYAN DANIEL
12 granted patents·13 pending applications·274 citations·filing 2005–2025
91Inventor score
Files withDECIPHERA PHARMACEUTICALS LLC22RAINES RONALD T1SMITH BRYAN DANIEL1WISCONSIN ALUMNI RES FOUND1
Top patents by PatentIndex Score
25 records- 0197US9187474B2Raf inhibitor compoundsDECIPHERA PHARMACEUTICALS LLC·Filed 2013·Granted Nov 17, 2015·60 cites·19 claims
- 0296US12285430B2Methods of treating disorders using CSF1R inhibitorsDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Apr 29, 2025·4 cites·18 claims
- 0396US11679110B2Methods of treating disorders using CSF1R inhibitorsDECIPHERA PHARMACEUTICALS LLC·Filed 2021·Granted Jun 20, 2023·24 cites·18 claims
- 0496US11103507B2Methods of treating disorders using CSF1R inhibitorsDECIPHERA PHARMACEUTICALS LLC·Filed 2019·Granted Aug 31, 2021·48 cites·30 claims
- 0595US9457019B2Methods for inhibiting tie-2 kinase useful in the treatment of cancerDECIPHERA PHARMACEUTICALS LLC·Filed 2014·Granted Oct 4, 2016·70 cites·42 claims
- 0695US9334267B2RAF inhibitor compoundsDECIPHERA PHARMACEUTICALS LLC·Filed 2013·Granted May 10, 2016·60 cites·17 claims
- 0780US12485120B2Methods of treating disorders using CSF1R inhibitorsDECIPHERA PHARMACEUTICALS LLC·Filed 2025·Granted Dec 2, 2025·0 cites·19 claims
- 0880US8962001B2Nuclease inhibitors and methods for their useWISCONSIN ALUMNI RES FOUND·Filed 2013·Granted Feb 24, 2015·2 cites·20 claims
- 0979US2022370423A1Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alphaDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
- 1078US2022370424A1Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alphaDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
- 1176US2022031678A1Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alphaDECIPHERA PHARMACEUTICALS LLC·Filed 2021·Application pending·0 cites
- 1274US8460684B2Nuclease inhibitors and methods for their useRAINES RONALD T·Filed 2005·Granted Jun 11, 2013·1 cites·33 claims
- 1371US2021015801A1Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alphaDECIPHERA PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 1470US2024415818A1Combination therapy for the treatment of gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Application pending·0 cites
- 1568US2025090506A1Combination therapy for the treatment of mastocytosisDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Application pending·0 cites
- 1667US7836821B2Fun dipperSMITH BRYAN DANIEL·Filed 2007·Granted Nov 23, 2010·5 cites·20 claims
- 1767US2020129489A1Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alphaDECIPHERA PHARMACEUTICALS LLC·Filed 2017·Application pending·0 cites
- 1861US11986463B2Combination therapy for the treatment of gastrointestinal stromal tumorDECIPHERA PHARMACEUTICALS LLC·Filed 2020·Granted May 21, 2024·0 cites·11 claims
- 1961US2025206729A1Dual raf and tubulin inhibitors and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Application pending·0 cites
- 2060US2024180923A1Methods of treating disorders with ulk inhibitorsDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Application pending·0 cites
- 2159US12102620B2Combination therapy for the treatment of mastocytosisDECIPHERA PHARMACEUTICALS LLC·Filed 2020·Granted Oct 1, 2024·0 cites·12 claims
- 2258US2019091217A1Methods for inhibiting tie-2 kinase useful in the treatment of cancerDECIPHERA PHARMACEUTICALS LLC·Filed 2018·Application pending·0 cites
- 2346US2023277522A9Methods for treating vascular malformationsDECIPHERA PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 2438US2017079966A1Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progressionDECIPHERA PHARMACEUTICALS LLC·Filed 2015·Application pending·0 cites
- 2536US2016101090A1Inhibition of trk kinase mediated tumor growth and disease progressionDECIPHERA PHARMACEUTICALS LLC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Bryan D. Smith files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →